Mylan refuses to testify at Senate hearing about EpiPen rebates to Medicaid

(By Ed Silverman for STAT)

In a move that angered a key Senate lawmaker, Mylan Pharmaceuticals has declined to testify at a planned Nov.30 Senate hearing to review a $465 million settlement the drug maker purportedly reached with the US Department of Justice for shortchanging Medicaid. Continue reading article here…


Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or